Virtu Financial (NASDAQ:VIRT) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.59 by 3.39 percent. This is a 12.86 percent decrease over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $561.04 million which beat the analyst consensus estimate of $328.27 million by 70.91 percent. This is a 3.07 percent increase over sales of $544.34 million the same period last year.
TCR2 Therapeutics Announces Topline Results From Phase 1 Portion Of gavo-cel Phase 1/2 Trial; Showed ‘Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%’
- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit
- Second RECIST partial response in ovarian cancer supports
